AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32557478 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Number of subjects: 0
Study 32557478 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine perfusion (MP)
Number of subjects: 0
Study 34300161 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CA‐CBT (16 sessions)
Number of subjects: 64
Study 34300161 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual CA‐CBT (8 sessions)
Number of subjects: 64
Study 34300161 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 64
Study 33775611 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective-suturing or sutureless technique (suRAPN)
Number of subjects: 92
Study 33775611 — intervention group
Group type: COMPARATOR
Intervention: Standard RAPN (stRAPN)
Number of subjects: 92
Study 33840928 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC video laryngoscope guided intubation using Frova introducer
Number of subjects: 140
Study 33840928 — intervention group
Group type: COMPARATOR
Intervention: C-MAC video laryngoscope guided intubation without Frova introducer
Number of subjects: 140
Study 36214737 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Care Plan Checklist for Evidence of Person-Centered Care Approaches for BPSD
Number of subjects: 103
Study 32290681 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive coping and perceived stress interventions
Number of subjects: 0
Study 33766422 — intervention group
Group type: COMPARATOR
Intervention: Prevenar13™ (PCV13) (_PPP)
Number of subjects: 425
Study 33766422 — intervention group
Group type: COMPARATOR
Intervention: Synflorix™ (PHiD-CV10) (_SSS)
Number of subjects: 425
Study 33766422 — intervention group
Group type: COMPARATOR
Intervention: Mixed primary series of PHiD-CV10 and PCV13 (SSSP)
Number of subjects: 425
Study 33766422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear discharge swabs (n = 108)
Number of subjects: 425
Study 34139404 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (12-week duration)
Number of subjects: 53
Study 34139404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 34139404 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 53
Study 34360184 — intervention group
Group type: EXPERIMENTAL
Intervention: G% (1RM test group)
Number of subjects: 25
Study 34360184 — intervention group
Group type: EXPERIMENTAL
Intervention: GPE (RPE group)
Number of subjects: 25
Study 35945770 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical therapy exercise program plus 20 minutes PBMT (650 nm, 5 mW, 1 cm², 6 Joules, 3 sessions/week for 8 weeks) plus traditional medical treatment
Number of subjects: 40
Study 35945770 — intervention group
Group type: COMPARATOR
Intervention: PBMT (same protocol as Group A, 3 sessions/week for 8 weeks) plus traditional medical treatment
Number of subjects: 40
Study 34454404 — intervention group
Group type: EXPERIMENTAL
Intervention: Postgraduate dermatology training
Number of subjects: 456
Study 34454404 — intervention group
Group type: COMPARATOR
Intervention: General community pharmacists
Number of subjects: 456
Study 34454404 — intervention group
Group type: COMPARATOR
Intervention: Community pharmacists
Number of subjects: 456
Study 32445052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 16
Study 32445052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32445052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 16
Study 35179523 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D limb scanning
Number of subjects: 30
Study 35179523 — intervention group
Group type: COMPARATOR
Intervention: Physical measurements
Number of subjects: 30
Study 33978833 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape juice (condition sugar)
Number of subjects: 122
Study 33978833 — intervention group
Group type: COMPARATOR
Intervention: Water (condition water)
Number of subjects: 122
Study 32202830 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care Program (ICP)
Number of subjects: 153
Study 32202830 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 153
Study 35276223 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with methotrexate (ADL-MTX)
Number of subjects: 61
Study 35276223 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab monotherapy (ADL)
Number of subjects: 61
Study 33248882 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention delivered by CMR physicians
Number of subjects: 25
Study 34428930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonothrombolysis (ultrasound-enhanced thrombolysis)
Number of subjects: 1102
Study 34428930 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis alone
Number of subjects: 1102
Study 34428930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonothrombolysis
Number of subjects: 1102
Study 34428930 — intervention group
Group type: COMPARATOR
Intervention: Control (Intravenous thrombolysis alone)
Number of subjects: 1102
Study 33305723 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole injection 100 mg
Number of subjects: 36
Study 33305723 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole injection 200 mg
Number of subjects: 36
Study 33305723 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole injection 300 mg
Number of subjects: 36
Study 33723616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training combined with neuromuscular electrical stimulation of the paraspinal muscles for 12 weeks
Number of subjects: 96
Study 33723616 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation for 12 weeks
Number of subjects: 96
Study 33115536 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric expressions
Number of subjects: 225
Study 33115536 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical presentations
Number of subjects: 225
Study 33115536 — intervention group
Group type: COMPARATOR
Intervention: Verbal expressions
Number of subjects: 225
Study 33115536 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Don't know' responses
Number of subjects: 225
Study 36098936 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 930
Study 36098936 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Number of subjects: 930
Study 36098936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study 33629803 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoregulated heavy slow resistance training (HSRT) combined with extracorporeal shockwave therapy (ESWT)
Number of subjects: 0
Study 33629803 — intervention group
Group type: COMPARATOR
Intervention: Autoregulated heavy slow resistance training (HSRT)
Number of subjects: 0
Study 33629803 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 0
Study 32818281 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtendon repair technique
Number of subjects: 64
Study 36192126 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course outpatient antibiotic therapy
Number of subjects: 0
Study 36192126 — intervention group
Group type: COMPARATOR
Intervention: Standard-course outpatient antibiotic therapy
Number of subjects: 0
Study 34014695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele.TAnDem (telephone-based cognitive-behavioral therapy) consisting of 12 sessions over 6 months
Number of subjects: 51
Study 34014695 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 51
Study 34185333 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-reduced platelet-rich plasma (PRP)
Number of subjects: 11
Study 34185333 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 11
Study 33845211 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks
Number of subjects: 792
Study 33845211 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 792
Study 33845211 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab in PD-L1+ ≥50% subgroup
Number of subjects: 792
Study 33845211 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel in PD-L1+ ≥50% subgroup
Number of subjects: 792
Study 33845211 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab in PD-L1+ ≥80% subgroup
Number of subjects: 792
Study 33845211 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel in PD-L1+ ≥80% subgroup
Number of subjects: 792
Study 33845211 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 792
Study 35856817 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Methotrexate 7.5 mg weekly for a maximum of 12 weeks
Number of subjects: 40
Study 35856817 — intervention group
Group type: COMPARATOR
Intervention: Oral Mini Pulse Betamethasone 3 mg weekly for a maximum of 12 weeks
Number of subjects: 40
Study 34251927 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Awareness and Perception Training (RAPT) program
Number of subjects: 5036
Study 34251927 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 5036
Study 35921241 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise programme consisting of close kinetic chain (CKC) exercises 2 days a week for 12 weeks, in addition to prophylactic treatment.
Number of subjects: 21
Study 35921241 — intervention group
Group type: COMPARATOR
Intervention: Conventional Treatment Group (CTG) received exercise training as described in the published literature.
Number of subjects: 21
Study 35921241 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) continued to receive prophylactic treatment during the study period.
Number of subjects: 21
Study 32126964 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 160
Study 32126964 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 160
Study 32126964 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study 36404406 — intervention group
Group type: EXPERIMENTAL
Intervention: HM3 LVAD
Number of subjects: 918
Study 36404406 — intervention group
Group type: COMPARATOR
Intervention: HMII LVAD
Number of subjects: 918
Study 36404406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HM3 group
Number of subjects: 918
Study 34444739 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine stoneground flour bread
Number of subjects: 23
Study 34444739 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse stoneground flour bread
Number of subjects: 23
Study 32266380 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of aspirin once daily
Number of subjects: 245
Study 32266380 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin twice daily
Number of subjects: 245
Study 32266380 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin thrice daily
Number of subjects: 245
Study 35405656 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives ($10 incentive when tested for HIV)
Number of subjects: 0
Study 35405656 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft commitment (behavioral nudge)
Number of subjects: 0
Study 35405656 — intervention group
Group type: COMPARATOR
Intervention: Information only
Number of subjects: 0
Study 34415356 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 3523
Study 34415356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3523
Study 32881764 — intervention group
Group type: EXPERIMENTAL
Intervention: Heading (n = 22)
Number of subjects: 39
Study 32881764 — intervention group
Group type: COMPARATOR
Intervention: Kicking-control (n = 17)
Number of subjects: 39
Study 35665724 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment (IMKT) + Non-resistance manual therapy (NRT)
Number of subjects: 120
Study 35665724 — intervention group
Group type: COMPARATOR
Intervention: Integrative Korean medicine treatment (IMKT)
Number of subjects: 120
Study 32279591 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable voltage electronic cigarette batteries
Number of subjects: 0
Study 34126263 — intervention group
Group type: EXPERIMENTAL
Intervention: Song-based, video-guided intervention for independent application of sunscreen during a 10-day intervention period.
Number of subjects: 96
Study 34126263 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher and student perceptions of intervention value and utility were evaluated during the intervention period.
Number of subjects: 96
Study 33065035 — intervention group
Group type: EXPERIMENTAL
Intervention: QVLP vaccine (30 μg haemagglutinin per strain)
Number of subjects: 10160
Study 33065035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10160
Study 33065035 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent inactivated vaccine (QIV; 15 μg haemagglutinin per strain)
Number of subjects: 10160
Study 36182540 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led delirium-prevention protocol
Number of subjects: 2566
Study 36182540 — intervention group
Group type: COMPARATOR
Intervention: Preintervention (baseline) period
Number of subjects: 2566
Study 34432727 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management program for 8 weeks
Number of subjects: 62
Study 34432727 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care (control)
Number of subjects: 62
Study 33235017 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental running program (EXP, n = 22)
Number of subjects: 50
Study 33235017 — intervention group
Group type: COMPARATOR
Intervention: Traditional military running program (TRA, n = 28)
Number of subjects: 50
Study 33235017 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental running program (EXP) after crossover
Number of subjects: 50
Study 35537105 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy as per protocol
Number of subjects: 3176
Study 34032510 — intervention group
Group type: EXPERIMENTAL
Intervention: van Leeuwen model
Number of subjects: 385
Study 34032510 — intervention group
Group type: EXPERIMENTAL
Intervention: Mehralivand model
Number of subjects: 385
Study 34032510 — intervention group
Group type: COMPARATOR
Intervention: PI-RADS plus PSAd strategy
Number of subjects: 385
Study 34032510 — intervention group
Group type: EXPERIMENTAL
Intervention: MRIERSPC, Radtke, Mehralivand models (without prior recalibration)
Number of subjects: 385
Study 35712008 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention‐assisted comfort care based on the PERMA model
Number of subjects: 100
Study 35712008 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 100
Study 34524157 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (50 μg)
Number of subjects: 86
Study 34524157 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (4 μg)
Number of subjects: 86
Study 32087175 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 174
Study 32087175 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 174
Study 36105122 — intervention group
Group type: COMPARATOR
Intervention: BCAA+FO supplement group (n=10)
Number of subjects: 29
Study 36105122 — intervention group
Group type: COMPARATOR
Intervention: BCAA group (n=10)
Number of subjects: 29
Study 36105122 — intervention group
Group type: COMPARATOR
Intervention: BCAA+FO group (n=10)
Number of subjects: 29
Study 33619708 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative thoracic paravertebral block with 0.5% bupivacaine
Number of subjects: 70
Study 33619708 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative oxycodone combined with nonopioid analgesics
Number of subjects: 70
Study 33619708 — intervention group
Group type: EXPERIMENTAL
Intervention: α-amylase levels
Number of subjects: 70
Study 33619708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 70
Study 32719129 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare bundled payment reform
Number of subjects: 0
Study 32719129 — intervention group
Group type: COMPARATOR
Intervention: Control group (areas without payment reform)
Number of subjects: 0
Study 36301543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotus valve
Number of subjects: 912
Study 36301543 — intervention group
Group type: COMPARATOR
Intervention: CoreValve/EvolutR
Number of subjects: 912
Study 36301543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 912
Study 33822898 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 1118
Study 33822898 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg at week 0, week 4, Q8W
Number of subjects: 1118
Study 33822898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1118
Study 33822898 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (both dosing regimens)
Number of subjects: 1118
Study 33822898 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (resolved enthesitis at week 24)
Number of subjects: 1118
Study 33822898 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (unresolved enthesitis at week 24)
Number of subjects: 1118
Study 34049789 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model incorporating institutional case volume
Number of subjects: 57804
Study 34049789 — intervention group
Group type: EXPERIMENTAL
Intervention: Case volume classification (50 or less, 50-100, 100-200, or more than 200 average cardiac surgery cases per year)
Number of subjects: 57804
Study 32555990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathyroid injection of dexamethasone (IID)
Number of subjects: 42
Study 32555990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 34664816 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg, twice a day
Number of subjects: 41
Study 34664816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 34664816 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 41
Study 32924685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg bolus before induction and 3 µg/kg/min infusion during surgery)
Number of subjects: 71
Study 32924685 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.5 mg/kg bolus before induction and 3 µg/kg/min infusion during surgery)
Number of subjects: 71
Study 35240075 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 cycles of venetoclax consolidation
Number of subjects: 70
Study 35240075 — intervention group
Group type: COMPARATOR
Intervention: Minimal residual disease-guided venetoclax consolidation
Number of subjects: 70
Study 33860177 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (20‐30 mg/70 kg) with overtone-based music
Number of subjects: 10
Study 33860177 — intervention group
Group type: COMPARATOR
Intervention: Psilocybin (20‐30 mg/70 kg) with Western classical music
Number of subjects: 10
Study 33860177 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (30 mg/70 kg) with chosen music (overtone-based or Western classical)
Number of subjects: 10
Study 36352620 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 30
Study 36352620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32022647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Psychodynamic Therapy (PDT)
Number of subjects: 47
Study 32022647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 47
Study 32022647 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy (PDT)
Number of subjects: 47
Study 32022647 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 47
Study 33721839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant emotions
Number of subjects: 466
Study 33721839 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant emotions
Number of subjects: 466
Study 33721839 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 466
Study 33991112 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm BOZD ortho-k lenses
Number of subjects: 70
Study 33991112 — intervention group
Group type: COMPARATOR
Intervention: 5 mm BOZD ortho-k lenses
Number of subjects: 70
Study 33991112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 32680548 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (30 g/day) with hypocaloric diet
Number of subjects: 60
Study 32680548 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypocaloric diet only)
Number of subjects: 60
Study 34391275 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage by a nurse
Number of subjects: 75
Study 34391275 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage by patient's family
Number of subjects: 75
Study 34391275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 32379608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 268
Study 32379608 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 268
Study 33395356 — intervention group
Group type: EXPERIMENTAL
Intervention: ORADUR-MPH
Number of subjects: 100
Study 33395356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35899977 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual film (SL‐APO)
Number of subjects: 40
Study 35899977 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg, positive control)
Number of subjects: 40
Study 35899977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32460773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive upper limb rehabilitation added to botulinum toxin-A
Number of subjects: 139
Study 32460773 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 139
Study 35816069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical supplement
Number of subjects: 0